PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Deintensification Doubled But Still Lags in Overtreated Older Diabetics

sulfonylureasinsulinGLP-1 receptor agonistsSGLT-2 inhibitorsmetformintype 2 diabetesolder adultsdeintensificationdeprescribingHbA1cADA guidelinescohort studyovertreatment Endocrinology / Diabetes / Obesity
Also in Geriatrics

Background Information

Exploring medication changes for older adults with diabetes.

Understanding medication changes in older adults can improve outcomes and reduce adverse effects. No abstract available; key results cannot be determined. The study appears to explore diabetes medication management, not opioid stewardship. Study lacks accessible details due to missing abstract.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Le P, Guo N, Misra-Hebert AD, Casacchia NJ, Yue Y, Gasoyan H, Taksler GB, Rothberg MB

Citation: Le P, Guo N, Misra-Hebert AD, et al. Intensification and Deintensification of Diabetes Medications Among Older Adults With Type 2 Diabetes. JAMA internal medicine. 2026;186(10):1278-1282. doi:10.1001/jamainternmed.2026.3483

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.